News Headlines

  1. ProMed Pharma Announces Acquisition Of Manufacturing Facility From Bora Pharmaceuticals 8/19/2025

    ProMed Pharma LLC, a leading provider of polymer-based drug delivery solutions, today announced the acquisition of a 28,000 square foot, state-of-the-art pharmaceutical manufacturing facility located at 2200 N Niagara Lane, Plymouth, Minnesota.

  2. Battelle And Aprecia Collaborate With U.S. Department Of Health And Human Services And U.S. Defense Advanced Research Projects Agency To Advance U.S. Drug Manufacturing Capability Utilizing 3D-Printed Technology To Produce Essential Medicines At The Point 8/19/2025

    Battelle and Aprecia have been awarded a U.S. Defense Advanced Research Projects Agency (DARPA) agreement to advance the research program titled Establishing Qualification Processes for Agile Pharmaceutical Manufacturing (EQUIP-A-Pharma) through funding from the U.S. Department of Health and Human Services (HHS) Administration for Strategic Preparedness and Response (ASPR) Office of Industrial Base Management and Supply Chain (IBMSC). ASPR's mission is to assist in preparing for, responding to, and recovering from public health emergencies and disasters.

  3. Skyhawk Therapeutics Announces Strategic Collaboration With Merck KGaA, Darmstadt, Germany To Discover Novel RNA-Targeting Small Molecules For Neurological Disorders 8/18/2025

    Skyhawk Therapeutics, Inc., a leader in the discovery and development of small molecules that modulate RNA expression, today announces a strategic research collaboration with Merck KGaA, Darmstadt, Germany, a leading science and technology company.

  4. Upperton Pharma Solutions Awarded VaxHub Sustainable Grant To Advance Oral Vaccine Delivery In Partnership With The University Of Oxford's Pandemic Sciences Institute 8/18/2025

    Upperton Pharma Solutions, a leading UK-based CDMO, has been awarded a grant as part of the first VaxHub Sustainable Platform Funding Call, in collaboration with the University of Oxford. The funding supports the development of an oral formulation for Adenovirus-vectored vaccines.

  5. WuXi Biologics Ireland Facility Receives First EMA Approval For Commercial Manufacturing Of Innovative Biologic 8/18/2025

    WuXi Biologics, a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced that its Dundalk, Ireland facility has received its first approval from European Medicines Agency (EMA) as a commercial manufacturing site for a global client’s innovative biologic.

  6. Vcare Enters Into Exclusive Partnership With Huadong Medicine To Commercialize Its Second-Generation JAK1 Inhibitor, VC005 Tablets, In China 8/15/2025

    Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) announced that it has entered into an exclusive strategic partnership with Huadong Medicine (Hangzhou) Co., Ltd., a wholly-owned subsidiary of Huadong Medicine Co., Ltd. (000963.SZ, "Huadong Medicine"), for the commercialization rights of Jiangsu Vcare's innovative product VC005 tablets in mainland China.

  7. ScaleReady Announces Award Of A G-Rex® Grant To The Gates Institute's Translational Sciences Laboratory 8/14/2025

    ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation and CellReady, today announced that the Translational Sciences Laboratory at Gates Institute, a leading contract development and manufacturing organization (CDMO) based at the University of Colorado Anschutz Medical Campus, has been awarded a $300,000 G-Rex® Grant to develop a modular G-Rex centric CAR T-cell manufacturing platform.

  8. Made Scientific And New Jersey Delegates Celebrate Grand Opening Of Flagship Cell Therapy Manufacturing Facility 8/14/2025

    Made Scientific, a leading U.S.-based cell therapy contract development and manufacturing organization (CDMO), held a ribbon-cutting ceremony yesterday to commemorate the grand opening of its new 60,000 sq. ft. GMP manufacturing facility and headquarters in Princeton, New Jersey.

  9. Superluminal Medicines Announces Collaboration With Eli Lilly And Company To Advance Small Molecule Therapeutics For Cardiometabolic Diseases And Obesity 8/14/2025

    Superluminal Medicines, a drug discovery company integrating AI/ML, protein dynamics, and structural biology to rapidly unlock the most challenging G protein-coupled receptors (GPCRs), today announced a collaboration with Eli Lilly and Company ("Lilly") to advance small molecule therapeutics targeting undisclosed GPCR targets relevant to cardiometabolic diseases and obesity.

  10. Avista Therapeutics And Forge Biologics Announce AAV Development And cGMP Manufacturing Partnership 8/13/2025

    Avista Therapeutics (“Avista”), a pre-clinical-stage biotechnology company developing novel AAV capsids with high efficacy and unique tropisms into innovative gene therapies for rare ophthalmic conditions, and Forge Biologics, (“Forge”), a leading manufacturer of genetic medicines and member of the Ajinomoto Bio-Pharma Services group, today announced a strategic partnership to advance the development and manufacturing of AVST-101, Avista’s lead gene therapy candidate targeting X-linked retinoschisis (XLRS), a serious inherited retinal disease.